LXEO.US Lexeo Therapeutics, Inc. Common Stock

Healthcare Biotechnology USA Stocks
3.23 USD
Close of Nov 17, 2026
2.55 10.99
Market cap
USD 265M
P/E
-
P/B
1.00x
ROE
-39.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is LXEO.US undervalued?

Graham number

The Graham number of Lexeo Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Lexeo Therapeutics, Inc. Common Stock fundamental analysis

No fundamental analysis for Lexeo Therapeutics, Inc. Common Stock yet.

Lexeo Therapeutics, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP…

Full company profile